乌司他丁联合头孢哌酮舒巴坦钠治疗ICU老年重症肺炎的效果分析

Analysis of the Effects of Ulinastatin Combined with Cefoperazone-Sulbactam on PCT and WBC in the Treatment of Severe Pneumonia in Elderly ICU Patients

目的探索乌司他丁联合头孢哌酮舒巴坦钠在ICU老年重症肺炎患者中的应用价值。方法纳入2023年3至2024年3月到三亚哈尔滨医科大学鸿森医院ICU就诊的100例老年重症肺炎患者,根据随机数字表发分为研究组与对照组,每组各50例。研究组给予乌司他丁联合头孢哌酮舒巴坦钠进行治疗,对照组给予头孢哌酮舒巴坦钠进行治疗。比较两组患者的降钙素原(PCT)、白细胞(WBC)水平、临床症状恢复时间、临床疗效及不良反应。结果治疗前,两组患者PCT和WBC水平均无显著差异(P>0.05);治疗后,两组患者PCT和WBC水平均降低(P<0.001),且研究组PCT和WBC水平显著低于对照组(P<0.001)。研究组患者退热时间、肺部炎症吸收时间、痰液颜色改变时间均显著短于对照组(P<0.001)。研究组临床有效率为98.00%,显著高于对照组的84.00%(P<0.05)。研究组不良反应发生率为8.00%,与对照组的10.00%对比,差异无统计学意义(P>0.05)。结论对ICU老年重症肺炎患者采取乌司他丁联合头孢哌酮舒巴坦钠进行治疗,可有效降低PCT和WBC水平、缩短临床症状恢复时间,临床疗效显著且不良反应风险低。

Objective To explore the value of ulinastatin combined with cefoperazone-sulbactam sodium in the treatment of elderly patients with severe pneumonia in the ICU.Methods 100 elderly patients with severe pneumonia admitted to the ICU of Hainan Sanya Harbin Medical University Hongsen Hospital from March 2023 to March 2024 were included in the study.They were randomly divided into the study group and the control group,with 50 patients in each group.The study group was treated with ulinastatin combined with cefoperazone-sulbactam sodium,while the control group was treated with cefoperazone-sulbactam sodium alone.Procalcitonin(PCT)and white blood cell(WBC)levels,clinical symptom recovery time,clinical efficacy,and adverse reactions were compared between the two groups.Results Before treatment,there were no significant differences in PCT and WBC levels between the two groups(P>0.05).After treatment,PCT and WBC levels decreased in both groups(P<0.001),while the study group showed significantly lower levels of PCT and WBC than those of the control group(P<0.001).The study group had significantly shorter fever reduction time,lung inflammation absorption time,and sputum color change time compared to the control group(P<0.001).The clinical efficacy rate in the study group was 98.00%,significantly higher than that(84.00%)in the control group(P<0.05).The incidence of adverse reactions in the study group was 8.00%,which compared to that(10.00%)in the control group,has no significant difference(P>0.05).Conclusions The combination of ulinastatin and cefoperazone-sulbactam sodium is effective in treating elderly ICU patients with severe pneumonia,as it significantly reduces PCT and WBC levels,shortens clinical symptom recovery time,has a remarkable clinical e fficacy,and carries a low risk of adverse reactions.